FDA Panel Backs Auxilium's (AUXL) XIAFLEX
More News related to AUXL
- Auxilium Pharmaceuticals to Announce Fourth Quarter and Full Year 2009 Results and Conduct Conference Call on Wednesday, February 17, 2010
- Morning Movers 2/3: HDIX, BGP, APKT, TDSC, CGX, NETL Higher; XIDE, VSR, PLNR, R, CNLG Lower
- Auxilium Announces U.S. Food and Drug Administration Approval for XIAFLEX(TM) for the Treatment of Dupuytren's Contracture
- Auxilium (AUXL) Announces FDA Approval for XIAFLEX
- BioSpecifics Technologies Corp. Announces FDA Approval of XIAFLEX(TM) for Treatment of Dupuytren's Contracture
More News related to FDA
- AspenBio Pharma (APPY) Reports Results from Interim Analysis for Ongoing Trial of AppyScore
- XenoPort (XNPT) Said FDA Moves PDUFA Date Due to February 11
- Dendreon (DNDN) CEO Says Provenge Salesforce Will Be 125 People, Sees Full Manufacturing Ability by Mid-2011
- U.S. FDA to Become More Stringent on Medical Imaging Equipment (GE, SI)
- BSD Medical (BSDM) Initiates Phase 3 Clinical Study of BSD-2000 Hyperthermia System
A FDA panel is backing Auxilium Pharmaceuticals (Nasdaq: AUXL) XIAFLEX drug to treat Dupuytren's contracture, a condition in which connective tissue in the hands hardens and contracts.
An FDA panel voted 12-0 in favor of XIAFLEX, saying it is a safe and effective alterative to surgery, and in some ways may be better than surgery.
Shares of Auxilium have been halted all day ahead of the news.
Related Categories
FDAStocks Mentioned
+0.00Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
